Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant congenital disorder characterized by progressive heterotopic bone formation. Currently, no definitive treatment exists for FOP. The activin receptor type IA / activin-like kinase 2 (ACVR1/ALK2) gene has been identified as the responsible gene for FOP, and disease-associated ALK2 mutations have been found. Chemical inhibitors to the pathogenic ALK2 receptors are considered possible medical agents for FOP, but their adverse effects on normal ALK2 and other receptors cannot be excluded. Here we describe another treatment strategy for FOP using allele-specific RNA interference (ASP-RNAi), and show modified small interfering RNAs (siRNAs) conferring allele-specific silencing against disease-causing ALK2 mutants found in FOP, without affecting normal ALK2 allele. Thus, the siRNAs presented here may become novel therapeutic agents for FOP, and their induced ASP-RNAi may pave the way for the achievement of radical treatment of FOP and/or for the relief of its severe symptoms.
INTRODUCTION
Fibrodysplasia ossificans progressiva (FOP; MIM#135100) is a rare autosomal dominant disorder characterized by congenital malformation of great toes and progressive heterotopic ossification resulting in skeletal metamorphosis. 1, 2 The activin receptor type IA/ activin-like kinase 2 (ACVR1/ALK2) gene has been identified as the gene responsible for FOP, 3 and a recurrent mutation, 617G4A(R206H), has been found in both familial and sporadic FOP cases of various ethnic groups. 3 In addition, other types of heterozygous ALK2 mutations have been also detected in patients with atypical FOP, for example, 1067G4A(G356D). 1, 2, 4 The pathogenic, mutant ALK2 receptor appears to be a highly sensitive bone morphogenetic protein (BMP) type I receptor to BMPs and external triggers, resulting in an apparently constitutively active ALK2 receptor, and thereby readily inducing heterotopic bone formation in FOP. 5, 6 Currently, there is no definitive treatment of FOP. Chemical inhibitors against the pathogenic (constitutively active) ALK2 receptors have been developed and could be possible medical agents for FOP. However, they can also inhibit the intracellular signaling of normal ALK2 and other BMP type I receptors (ALK3 and ALK6). 7 -9 Thus, adverse effects of the inhibitors may be a major problem to be solved before using them for treatment of FOP.
In this report we show modified small interfering RNAs (siRNAs) conferring allele-specific RNAi against disease-causing ALK2 mutants found in FOP patients without affecting normal ALK2 allele, and we propose another treatment strategy for FOP by means of allele-specific silencing.
RESULTS AND DISCUSSION
Specific inhibition of the disease-causing ALK2 alleles by RNAi could be a potential way for avoidance of adverse effects on normal ALK2 and other receptors, 10 and further for the achievement of treatment of FOP. To achieve such an allele-specific silencing by RNAi (ASP-RNAi), it is vital to design siRNAs capable of discriminating mutant alleles from normal alleles; but it is quite difficult. Our previously established assay system with two reporter alleles encoding the Photinus and Renilla luciferase genes carrying mutant and wild-type allelic sequences in their 3¢-untranslated regions may solve the problem and allow for determination of such siRNAs. 11 -14 Briefly, test siRNAs are co-transfected with the mutant and wild-type reporter alleles and the bgalactosidase gene as a control into HeLa cells, and 24 h after transfection, dual-luciferase and b-galactosidase assays are carried out. Note that the transfected cells are heterozygous with the mutant and wildtype reporter alleles; thus, the effects of the test siRNAs on suppression of both the target mutant and non-target wild-type reporter alleles can be simultaneously examined. Using the assay system, we attempted to design competent siRNAs conferring allele-specific silencing against two distinct ALK2 mutants found in FOP: one is ALK2_617G4A(R206H) and the other is ALK2_1067G4A(G356D), which is a rare mutation found in a variant FOP case. 4 The mutant ALK2 reporter alleles carrying the ALK2_ 617G4A(R206H) and ALK2_1067G4A(G356D) mutations and their corresponding normal (wild-type) reporter alleles were constructed (Supplementary Figure S1) . SiRNAs targeting the mutant ALK2 were chemically synthesized (Supplementary Tables S1 and S2) and subjected to screening (assessment) by the assay system with the reporter alleles. The first screening of the siRNAs perfectly matched the mutant sequences, resulted in a negative consequence except for the siG356D_A9 siRNA (Supplementary Figure S2) ; siG356D_A9 appeared to induce allele-specific silencing in a moderate level.
Modification of siRNAs such as introduction of mismatched base(s) into siRNAs often provides improvement in allele discrimination of the modified siRNAs, 12,14 thereby enhancing ASP-RNAi. It is known that nucleotide mismatches between siRNAs and their target RNAs can influence RNAi activity; however, critical nucleotide position(s) and kinds of nucleotide mismatches for conferring allele discrimination are still unpredictable: this may be because different siRNAs have different features depending upon their different nucleotide sequences. Therefore, modified siRNAs must be examined one by one for their allele discrimination abilities, and our assay system seems to be useful for such an assessment.
We designed various mismatched siRNAs (Supplementary Tables S1 and S2) and tested them by the assay system. From a series of assessment (Supplementary Figures S3 and S4 ), the siR206H_A9(C14) and siG356-D_A10(A13) modified siRNAs showed a marked improvement of their allele-specific silencing against the ALK2_617G4A(R206H) and ALK2_1067G4A(G356D) mutant reporter alleles, respectively (Figures 1a and b and Figures 1c and d, respectively) . The 50% inhibitory concentrations (IC 50 values) of the siRNAs further verified their remarkable allele discrimination (Figures 1b and d) : the IC 50 values of siR206-H_A9(C14) and siG356D_A10(A13) against their target mutant alleles were 0.61 and 0.27 nM, respectively, whereas the IC 50 values against the normal alleles were 420 nM, suggesting that the siR206H_A9(C14)-and siG356D_A10(A13)-modified siRNAs have the potential for suppressing the mutant ALK2 alleles carrying 617G4A(R206H) and 1067G4A (G356D), respectively, without affecting the normal ALK2 allele.
We examined knockdown potencies of the siR206H_A9(C14)-and siG356D_A10(A13)-modified siRNAs against bona fide mutant ALK2 receptors by introduction of the siRNAs and expression plasmid carrying the mutant (ALK_R206H or ALK_G356D) or normal ALK2 cDNA into C2C12 myoblasts. As shown in Figures 2a and b , the modified siRNAs successfully inhibited the expression of their target mutant receptors without inhibiting the expression of the normal ALK2 receptor.
When the modified siRNAs and expression plasmids were introduced into cells together with the BMP-specific luciferase reporter gene (IdWT4F-luc) whose expression is induced by mutant ALK2 receptors, 15 the siRNAs significantly and specifically inhibited the IdWT4F-luc activities induced by their target mutant ALK2 receptors; however, they did not induce any suppression to the activities involving normal or non-target mutant ALK2 receptors (Figure 2c ). In addition, it should be noted that the siRNAs triggered no inhibition of the IdWT4F-luc activity induced by ALK2_Q207D that was another mutant ALK2 receptor studied as a control. Taken together, these findings suggest that the siR206H_A9(C14)-and siG356D_A10(A13)-modified siRNAs can induce a specific inhibition against their target mutant ALK2 receptors without suppressing normal ALK2 receptor.
Next we examined the effects of the modified siRNAs on diseasecausing allele specific silencing against endogenous ALK2 mutants in lymphoblastoid cells established from FOP patients carrying the ALK2_R206H or ALK2_G356D allele: the lymphoblastoid cell might be a useful model for examining the BMP pathway in FOP patients. 16 Introduction of the IdWT4F-luc reporter gene into the lymphoblastoid cells revealed that: (1) the IdWT4F-luc activity was significantly upregulated in FOP patient cells expressing ALK2_R206H, and (2) the level of the IdWT4F-luc activity in another patient cells expressing ALK2_G356D was as low as that in healthy individual cells (N001; Figure 3a ). These results were consistent with our previous finding that ALK2_G356D had less activity than ALK2_R206H. 17 On the basis of the data, we introduced the siR206H_A9(C14) siRNA together with the IdWT4F-luc reporter gene into patient cells expressing ALK2_R206H. The result demonstrated significant reduction of the IdWT4F-luc activity by siR206H_A9(C14) ( Figure 3b) ; and marked decrease in the ALK2_R206H transcript was consistently detected, whereas the level of the normal ALK2 transcript, by contrast, remained unchanged ( Figure 3c ). Therefore, these findings strongly suggest that ASP-RNAi by our modified siRNAs can produce a specific inhibition against the pathogenic, constitutively active BMP signaling caused by mutant ALK2 receptors in FOP, and also confers few adverse effects on normal ALK2 receptor.
In conclusion, although chemical inhibitors to the BMP type I receptors could be possible medicinal agents for FOP, 5,8 they further affect normal ALK2 receptor 7 and other BMP type I receptors, 9 as well as pathogenic (mutant) ALK2 receptors. Thus, the risk of adverse effects of the inhibitors cannot be excluded at present, and such problems remain to be solved. In this study, we showed modified (mismatched) siRNAs conferring ASP-RNAi against two distinct disease-causing ALK2 alleles without affecting normal ALK2 allele. Therefore, the siRNAs may be capable of becoming novel medical agents for FOP, and diseasecausing allele specific silencing by ASP-RNAi may provide patients with a safe treatment with few adverse effects.
Disease-causing ALK2 mutations other than ALK2_617G4 A(R206H) and ALK2_1067G4A(G356D) may also be targets for ASP-RNAi, and our assessment system may allow for designing competent siRNAs conferring disease-causing allele specific silencing targeting such ALK2 mutants. Therefore, diagnoses including ALK2 mutation analysis by PCR-direct sequencing or TaqMan probes are vital for selection of appropriate treatment of FOP. 
To achieve in vivo ASP-RNAi, drug delivery system for siRNAs is also vital; and drug delivery system using stealth liposomes 18 and atelocollagen, 19 ,20 which appears to reduce recognition by the reticuloendothelial system, may be promising. To establish a safe and stable transport of siRNAs in vivo for RNAi therapy, more extensive studies remain to be carried out in the future.
Finally, RNAi therapy as another medical treatment strategy might pave a new path for the achievement of curative treatment of FOP and/or for relief of its severe symptoms; and our current study may further shed some light on the availability of ASP-RNAi as a diseasecausing allele specific silencing tool, for medical treatment of intractable diseases caused by dominant-positive alleles, such as FOP. 
MATERIALS AND METHODS

Cell culture
HeLa and C2C12 cells were grown at 37 1C in Dulbecco's modified Eagle's medium (Wako, chuo-ku, Osaka, Japan) supplemented with 10% and 15% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), respectively, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (Wako) in a 5% CO 2 humidified chamber. Epstein -Barr virus-transformed human lymphoblastoid cell lines were cultured at 37 1C in RPMI1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (Japan Bio Serum, Fukuyama, Hiroshima, Japan), 110mgl À1 sodium pyruvate (Wako), 4500 mg l À1 Dglucose (Wako), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (GIBCO, Carlsbad, CA, USA) in a 5% CO 2 humidified chamber. The Ethics Committees of the National Center of Neurology and Psychiatry, National Omuta Hospital and Saitama Medical University approved the study with Epstein -Barr virustransformed human lymphoblastoid cell lines derived from FOP patients.
DNA and RNA oligonucleotides
DNA oligonucleotides and siRNAs used in this study were obtained from Sigma-Aldrich. The sequences of the synthesized oligonucleotides are indicated in Supplementary Tables S1, S2 and S3.
Construction of mutant and wild-type reporter alleles
Mutant and wild-type reporter alleles were constructed as described previously. 11, 13 Briefly, phRL -TK (Promega, Fitchburg, WI, USA) and pGL3-TK plasmids encoding the Renilla and Photinus luciferase genes, respectively, were digested with XbaI and NotI, and subjected to ligation with synthetic oligonucleotide duplexes corresponding to the ALK2 normal, R206H (617G4A) and G356D (1067G4A) mutant alleles (Supplementary Figure  S1) . The oligonucleotide sequences for the construction of the reporter alleles are indicated in Supplementary Table S3 .
Assessment of siRNAs
Transfection of designed siRNAs together with the constructed reporter alleles, and luciferase and b-galactosidase assays were carried out as described previously. 11, 13 Briefly, the day before transfection, HeLa cells were trypsinized, diluted with fresh medium without antibiotics and seeded into 96-well culture plates (B1Â10 5 cells per cm 2 ). The pGL3 -TK-backbone reporter allele plasmid (60 ng), phRL-TK-backbone reporter allele plasmid (10 ng) and pSV-b-galactosidase control plasmid (20 ng; Promega) were co-transfected with designed siRNA (20 nM , final concentration) into each well using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions. Twenty-four hours after transfection, cell lysate was prepared and the expression levels of the Photinus and Renilla luciferases and bgalactosidase were examined by Dual-Luciferase reporter assay system (Promega) and Beta-Glo assay system (Promega), respectively. The luminescent signal was measured by a Fusion Universal Microplate Analyzer (PerkinElmer, Waltham, MA, USA). The levels of mutant and wild-type luciferase reporter allele activities were normalized to the level of b-galactosidase activity as a control, and the resultant ratios of the mutant and wild-type reporter allele activities in the presence of the test siRNAs were further normalized to the control ratios obtained in the presence of a non-silencing siRNA (siControl).
For examination of dose-dependent inhibition of siRNA (IC 50 of siRNA), the plasmids described above were co-transfected with an increasing amount of each siRNA (0, 0.001, 0.005, 0.02, 0.08, 0.32, 1.25, 5, 10 and 20 nM (final concentration)) into each well using Lipofectamine 2000 transfection reagent. Twenty-four hours after transfection, the expression of luciferase and bgalactosidase was examined as described above. The data were fitted to the Hill equation (Hill coefficient; n¼1) and IC 50 values were determined.
Examination of active BMP signaling pathway using pIdWT4F -luc plasmid
The IdWT4F -luc reporter plasmid carrying the Photinus luciferase gene driven by the Id1 promoter, which is activated by BMP signaling, was used, 15 and the basic assay system for the BMP pathway using C2C12 myoblast cells followed the previous study. 17 The day before transfection, C2C12 myoblast cells were trypsinized and seeded into 24-well culture plates (B1Â10 5 cells per cm 2 ) in culture medium without antibiotics. Co-transfection of the IdWT4F -luc plasmid (100 ng per well) together with normal-or mutant-type ALK2-V5 expression plasmid (200 ng per well), 15, 17 designed siRNA duplexes (20 nM, final concentration) and phRL -TK plasmid (50 ng per well) as a control was carried out using Lipofectamine 2000 transfection reagent. Two days after transfection, cell lysate was prepared and the expression levels of luciferase reporter genes were examined by Dual-Luciferase reporter assay system (Promega) according to the manufacturer's instructions. The luminescent signals were measured by a Fusion Universal Microplate Analyzer (PerkinElmer).
Western blot analysis
Equal amount of proteins was separated by SDS-PAGE with 10% polyacrylamide gels (10% T, 3.3% C), and electrophoretically blotted onto PVDF membranes (Millipore, Billerica, MA, USA). The membranes were blocked in blocking solution (5% skim milk in phosphate-buffered saline containing 0.05% Tween-20), and incubated with 1/5000 diluted anti-V5 antibody (Invitrogen) or 1/20 000 diluted mouse anti-a tubulin monoclonal antibody (Sigma-Aldrich) followed by washing in phosphate-buffered saline containing 0.05% Tween-20. After washing, further incubation with 1/5000 diluted horseradish peroxidase-conjugated anti-mouse IgG (Sigma-Aldrich) was carried out. Antigen -antibody complexes were visualized using Immobilon Western Chemiluminescent HRP Substrate (Millipore). The signal intensities of the visualized bands were measured by a Scion Image (Scion Corporation, Frederick, MD, USA). The data of the ALK2-V5 band were normalized to the intensity of the a-tubulin band, and further normalized to those obtained from naïve (nontreated) cells.
Electroporation
Introduction of the pIdWT4F -luc and phRL -TK plasmids together with siRNA into lymphoblastoid cells was carried out by means of the Nucleofector system (Amaxa, Basel, Switzerland) according to the manufacturer's instructions. Briefly, the cells (1Â10 6 cells per transfection) were suspended in 100 ml of electroporation buffer (Cell Line Nucleofector Solution V; Amaxa) containing 5 mM of siRNA, 300 ng of pIdWT4F -luc and 200 ng of phRL -TK plasmid. The transfection mixtures were subjected to electroporation with the U-005 pulsing program. After electroporation, the cells were immediately transferred into six-well culture plates containing pre-warmed culture medium and were incubated for 2 days.
Direct sequencing
Total RNAs were extracted from lymphoblastoid cells, which were cultured for 2 days after electroporation, and subjected to cDNA synthesis with Oligo(dT) 15 primers (Promega) and a Superscript III reverse transcriptase (Invitrogen) according to the manufacturer's instructions. PCR was carried out with the cDNA as a template and a primer set for amplification of a region containing the ALK2_R206H(617G4A) mutation using the GeneAmp PCR system 3700 (Applied Biosystems, Carlsbad, CA, USA). The thermal cycling profiles were as follows: heat denaturation at 94 1C for 1 min, 30 cycles of amplification including denaturation at 98 1C for 10 s, and annealing and extension at 68 1C for 1 min. The resultant PCR products were purified by a PCR and Gel purification kit (BEX, Itabashi-ku, Tokyo, Japan) according to the manufacturer's instructions, and subjected to direct sequencing by means of the ABI 3730 xl DNA Analyzer (Applied Biosystems). The sequences of the PCR and direct-sequencing primers were as follows: ALK2(R206H) primer set:
5¢-CACCACCAATGTTGGAGACAGC-3¢ 5¢-CTGAACCATGACTTCTCATCACG-3¢.
Statistical analysis
To examine the effect of disease-causing allele-specific RNAi knockdown, all statistical analysis was carried out using analysis of variance. When significant difference was shown by analysis of variance, Tukey's post hoc test was further carried out. The level of statistical significance was set at 0.05.
